United States: Weeks II: Innovator Liability Finds A Sweet Home In Alabama

Last week, the Supreme Court of Alabama confirmed its January 2013 holding that manufacturers of brand drugs can be liable for injuries caused by generic drugs. Weeks v. Wyeth, Inc., No. 1101397, slip op. (Ala. Aug. 15, 2014). Though the recent ruling puts Alabama in a very small minority of jurisdictions recognizing "innovator liability," it still represents a state supreme court holding that exposes brand drug manufacturers to liability they had not previously known. The ruling will likely result in significant new filings by the plaintiffs' bar in Alabama, and renewed arguments by them for other jurisdictions to follow Alabama's reasoning.


The Weeks case was originally decided in January 2013.1 In that opinion, the Alabama court became the first state supreme court to hold that brand drug manufacturers could be liable for injuries caused by generic drugs because the warnings and labels relied on were those of the brand drug. That ruling was contrary to the overwhelming majority of other courts, both trial courts and appellate courts alike who ruled against liability unless the drug ingested was from the brand drug company. The Supreme Court of Alabama was excoriated by many for deciding such an important question without oral argument. When the court decided to rehear the case, this time with oral argument, many in the pharmaceutical industry viewed this as an omen that reversal was likely. As time passed, it was thought the court might be carefully crafting a new opinion.

That hope was misplaced. The new Weeks opinion is surprising and disappointing to the pharmaceutical industry; it essentially re-states the original opinion despite the fact that it had been nearly one year since oral argument and many courts had weighed in on this issue in the intervening year and a half since the first opinion.


Our previous client alert examined the rationale behind the original holding. Essentially, the Supreme Court of Alabama held that it was foreseeable that a generic drug user's doctor would rely on representations by a brand drug manufacturer. In reaching this conclusion, the court relied on PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), which interpreted federal statutes and regulations as requiring generic drug manufacturers to copy brand drug manufacturers' labels. Unlike most other courts that have examined this issue, theWeeks court found that the foreseeability deriving from the federal regulatory scheme was sufficient to establish that the brand drug manufacturer owed the generic drug user a duty of care.

In reaching this decision once again (Weeks II), the court highlighted Alabama law regarding misrepresentation and "the fact that two parties have had no contractual relationship or other dealings does not preclude the finding of a legal duty not to make a material misrepresentation or to suppress a material fact." The majority concluded its opinion by reiterating that the fraud or misrepresentation claim at issue here premises liability not on "a defect in the product itself but as a result of statements made by the brand-name manufacturer that Congress, through the FDA, has mandated be the same on the generic version of the brand-name drug."


Justice Shaw specially concurred to clarify and defend the majority's opinion. He noted several points. First, the court's holding in no way meant that a company could generally be held liable for products it did not manufacture. Second, the court did not create new law. Instead, it applied existing Alabama law dealing with fraudulent conduct. He found that Alabama case law "generally holds that a duty to disclose may be owed to a person with whom the defendant has had no prior dealings, specifically, where there is a 'duty' not to make a false representation."

Third, the majority opinion is extremely narrow and would not apply outside the pharmaceutical context. This appears to be in direct response to critics who have "either shamefully misrepresented our holding or bordered on the hysterical" in response to the original Weeks opinion. Fourth, "no decision of any other jurisdiction addresses the precise question of Alabama law discussed in our answer."

Finally, Justice Shaw rejected the notion that the decision might stifle business. Instead, the court's decision "epitomizes the kind of judicial restraint that should be expected of an appellate court."


Three justices dissented. Chief Justice Moore felt the court should not have accepted the certified question because the answer was not dispositive of the case in the trial court. Justice Parker felt the court overstepped its authority, especially because he interpreted Mensing and Mutual Pharmaceutical Co. v. Bartlett, 131 S. Ct. 2567 (2013), as making "clear that [a generic drug] consumer is left without a remedy absent a legislative change by Congress."

Justice Murdock passionately dissented, penning an opinion equal in length to that of the majority's. He opened by quoting Alexander Hamilton and invoking the great American "spirit of enterprise" to highlight the injustice that would no doubt result from the court's holding. The dissent's reasoning was twofold. First, every other court (with the exception of Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (2008) and Kellogg v. Wyeth, Inc., 762 F. Supp. 2d 694 (D. Vt. 2010)) that had evaluated this issue disagreed with this court. Second (not content with the herd mentality argument), Justice Murdock fell back on the tried-and-true premise that this would "stretch the concept of foreseeability too far." Foster v. Am. Home Prods., 29 F.3d 165, 171 (4th Cir. 1994). Justice Murdock's variation on this theme was that foreseeability alone is insufficient to create a duty; in addition to foreseeability there must be a relationship between the two parties.

After conducting an extensive survey of decisions on the issue, Justice Murdock came full circle, predicting the negative impact that the court's holding would have on free enterprise. He worried that brand drug manufacturers would be unable to predict their liability, and this would create an insurability issue. Meanwhile, the court's reasoning could spill over into areas beyond pharmaceuticals and compound the problem.


Justice Murdock's concerns about the court's decision reaching beyond drugs are unnecessarily alarmist, given the unique federal regulatory scheme governing drugs and the stringent requirements that generic drug manufacturers maintain labels identical to those of the brand drug manufacturer's. However, innovator liability is now the law of Alabama and brand drug manufacturers should be concerned that filings there will increase. While choice of law rules may prevent out-of-state plaintiffs from taking advantage of Alabama law, the end result remains to be seen. It also remains to be seen whether the pharmaceutical industry will encourage the Alabama legislature to establish new product liability law to overcome the ruling, rather than face unlimited liability for another company's drugs.


1 See "Weeks Defies Years of Jurisprudence", Morrison and Foerster client alert.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Erin M. Bosman
Julie Y. Park
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions